These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38972017)

  • 1. Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.
    Chida K; Oshi M; Roy AM; Sato T; Takabe MP; Yan L; Endo I; Hakamada K; Takabe K
    Breast Cancer Res Treat; 2024 Jul; ():. PubMed ID: 38972017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Jul; ():. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Res Sq; 2024 Mar; ():. PubMed ID: 38585981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and
    Li Y; Dong W; Zhang P; Zhang T; Ma L; Qu M; Ma X; Zhou X; He Q
    Front Cell Dev Biol; 2021; 9():750897. PubMed ID: 34733851
    [No Abstract]   [Full Text] [Related]  

  • 5. High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    Wu R; Patel A; Tokumaru Y; Asaoka M; Oshi M; Yan L; Ishikawa T; Takabe K
    Breast Cancer Res Treat; 2022 May; 193(1):49-63. PubMed ID: 35249172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric cancer with enhanced myogenesis is associated with less cell proliferation, enriched epithelial-to-mesenchymal transition and angiogenesis, and poor clinical outcomes.
    Chida K; Oshi M; An N; Kanazawa H; Roy AM; Mann GK; Yan L; Endo I; Hakamada K; Takabe K
    Am J Cancer Res; 2024; 14(1):355-367. PubMed ID: 38323295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
    Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
    Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
    Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.
    Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High miR-200c expression is associated with suppressed epithelial-mesenchymal transition, TGF-β signaling and better survival despite enhanced cell proliferation in gastric cancer patients.
    Shichiri K; Oshi M; Ziazadeh D; Endo I; Takabe K
    Am J Cancer Res; 2023; 13(7):3027-3040. PubMed ID: 37560006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast Cancers.
    Santarosa M; Baldazzi D; Armellin M; Maestro R
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
    Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
    Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
    Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC;
    Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma.
    Ramos-Santillan V; Oshi M; Nelson E; Endo I; Takabe K
    World J Oncol; 2024 Apr; 15(2):257-267. PubMed ID: 38545476
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Oshi M; Ziazadeh D; Wu R; Chida K; Yamada A; Yamamoto S; Narui K; Yan L; Ishikawa T; Endo I; Takabe K
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
    Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
    Front Oncol; 2022; 12():976959. PubMed ID: 36119527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    Min A; Kim K; Jeong K; Choi S; Kim S; Suh KJ; Lee KH; Kim S; Im SA
    Sci Rep; 2020 Jul; 10(1):12506. PubMed ID: 32719318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
    Kadouri L; Kote-Jarai Z; Hubert A; Durocher F; Abeliovich D; Glaser B; Hamburger T; Eeles RA; Peretz T
    Br J Cancer; 2004 May; 90(10):2002-5. PubMed ID: 15138485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.